Trial Profile
Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP 690,550 in Patients With Active Rheumatoid Arthritis on Background Methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ORAL-Standard
- Sponsors Pfizer
- 15 Nov 2023 Results of a mediation modeling analysis presented at the ACR Convergence 2023
- 05 Apr 2022 Results of post-hoc pooled analysis (ORAL Scan; ORAL Standard; ORAL Sync) assessing impact of tofacitinib on fatigue, sleep, and HRQoL and explored associations between fatigue, related patient-reported outcomes (PROs), and disease activity in RA patients, published in the Arthritis Research and Therapy.
- 01 Mar 2022 Results evaluating the impact of tofacitinib using posthoc analysis of phase III and phase IIIb/IV trials published in The Journal of Rheumatology